Relay Therapeutics

Company snapshot

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By apply

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Relay Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Relay Therapeutics.

1. Jun 8, 2026 Clinical update

   RLY-2608-102 — Phase 3

2. Jun 5, 2026 Clinical update

   RLY-2608, RLY-2608 — Phase 2

3. Jun 5, 2026 Clinical update

   RLY-2608 — Phase 2

4. May 23, 2026 Clinical update

   RLY-2608 — Phase 3

5. May 23, 2026 Clinical update

   RLY-5836 — Phase 1

View all clinical trial activity →

• What is Relay Therapeutics?

  Relay Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker RLAY. Primary therapeutic focus areas include PIK3CA Mutation, PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation, PIK3CA-Related Overgrowth Sp

• Is Relay Therapeutics publicly traded?

  Yes. Relay Therapeutics is listed with ticker RLAY on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Relay Therapeutics develop or market?

  We link 7 drug profile(s) where Relay Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/relay-therapeutics#company-drugs.

• What are the latest developments for Relay Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Relay Therapeutics focus on?

  Relay Therapeutics focuses on PIK3CA Mutation, PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation, PIK3CA-Related Overgrowth Spectrum (PROS) based on our analysis of their pipeline programs and drug development activities.